The active ingredient in Stelara is ustekinumab. (An active ingredient is what makes a drug work.) The drug comes as a liquid solution you receive as a subcutaneous injection (an injection under ...

Before injecting Stelara for the first time, talk with your doctor. They’ll show you how to inject the drug safely and help determine which injection site is best for you. Subcutaneous ...

Companies in the multi-billion dollar psoriasis market are vying to be the next standard of treatment, and a flood of new data from three drugs showing them superior to Humira and Stelara.

Stelara is a biologic medicine used to treat moderate to severe Crohn’s disease and ulcerative colitis. Crohn’s disease and ulcerative colitis are inflammatory bowel diseases that cause ...

The Food and Drug Administration (FDA) has approved Imuldosa ™ (ustekinumab-srlf), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases.

Option Care Health ( NASDAQ: OPCH) sharers fell over 4% on Monday, after Goldman Sachs downgraded the company to Neutral from ...

Dong-A-ST's Imuldosa (ustekinumab-srlf/DMB-3115), a biosimilar to Stelara, has won the Food and Drug Administration’s approval. “This FDA approval indicates ...

The drug is the first in J&J’s portfolio to deliver ... the company is already seeing hits to its big-selling Stelara. Biosimilars in the U.S. will swarm the market in 2025, with Amgen and ...

Goldman Sachs downgraded Option Care Health (OPCH) to Neutral from Buy with a $27 price target. The firm had previously held the view that ...

Experts predict that physicians may favour emerging biosimilar versions of Stelara over more effective originator IL-23 drugs.

J&J's quarterly drug sales across segments Sales of blockbuster psoriasis drug Stelara fell 6.6% to $2.68 billion in the third quarter, but beat analyst estimates of $2.43 billion. Stelara has ...

The growth from Carvykti and Tremfya comes as J&J prepares for biosimilar competition to its second best-selling drug, Stelara, in January 2025. Biosimilars have already arrived in Europe and ...